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Background-—Long-term prognosis of acute pulmonary edema (APE) remains ill deﬁned.
Methods and Results-—We evaluated demographic, echocardiographic, and angiographic data of 806 consecutive patients with
APE with (CAD) and without coronary artery disease (non-CAD) admitted from 2000 to 2010. Differences between hospital and
long-term mortality and its predictors were also assessed. CAD patients (n=638) were older and had higher incidence of diabetes
and peripheral vascular disease than non-CAD (n=168), and lower ejection fraction. Hospital mortality was similar in both groups
(26.5% vs 31.5%; P=0.169) but APE recurrence was higher in CAD patients (17.3% vs 6.5%; P<0.001). Age, admission systolic blood
pressure, recurrence of APE, and need for inotropics or endotracheal intubation were the main independent predictors of hospital
mortality. In contrast, overall mortality (70.0% vs 57.1%; P=0.002) and readmission for nonfatal heart failure after a 45-month
follow-up (10–140; 17.3% vs 7.6%; P=0.009) were higher in CAD than in non-CAD patients. Age, peripheral vascular disease, and
peak creatine kinase MB during index hospitalization, but not ejection fraction, were the main independent predictors of overall
mortality, whereas coronary revascularization or valvular surgery were protective. These interventions were mostly performed
during hospitalization index (294 of 307; 96%) and not intervened patients showed a higher risk proﬁle.
Conclusions-—Long-term mortality in APE is high and higher in CAD than in non-CAD patients. Considering the different in-hospital
and long-term mortality predictors herein described, which do not necessarily involve systolic function, it is conceivable that a
more aggressive interventional program might improve survival in high-risk patients. ( J Am Heart Assoc. 2016;5:e002581 doi:
10.1161/JAHA.115.002581)
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A cute heart failure, which includes a variety of cardiacconditions such as cardiogenic shock, acute decompen-
sation of chronic heart failure, right ventricular failure, and
acute pulmonary edema (APE), accounts for an increasing
number of deaths and hospital admissions.1–5 Although these
presentations have their own proﬁle, reports generally pool data
from the different subsets and outcomes are presented as from
a single entity.1–3,5,6 APE, however, may be considered a
distinct condition because it develops abruptly, most often
within the ﬁrst hour from symptom onset, and it is often
triggered by elements different from those causing a gradual
decompensation of chronic heart failure.1,7–10 Hence, it is
suspected that mechanisms of APE may vary from those of
decompensated heart failure.1,10
Several recent studies have reported on the 1-year
prognosis of patients with acute heart failure4,11–16 and 3
have analyzed longer follow-up,15–17 one of them with
decompensated heart failure and pulmonary edema.17 In
contrast, long-term follow-up in patients with well-deﬁned APE
has been limited to 1 year and has been described in only 2
old reports with a reduced number of patients.7,18 Moreover,
causes of death in the follow-up were not investigated.
Thus, in the present study, we analyzed the in-hospital and
long-term follow-up events in patients with APE. We also
analyzed the causes of death, the prognostic predictors, and
the possible differences between patients with and patients
without CAD as the main underlying heart disease.
Methods
Patients
From January 2000 to December 2010, 806 consecutive
patients with APE admitted to our acute cardiac care unit
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were included. APE was deﬁned as orthopnea of ≤6 hours
with bilateral rales, hypoxemia (arterial oxygen saturation
<90%), and radiographic evidence of alveolar and/or intersti-
tial pulmonary edema. Oxygen saturation was assessed on
admission and blood pressure, by cuff, and heart rate were
measured at ﬁrst medical attention. Also, a chest X-ray and a
standard 12-lead electrocardiogram (ECG) were performed on
hospital arrival. Serial blood samples for myocardial necrosis
markers (creatine kinase MB [CK-MB] and troponin I) were
drawn every 4 to 6 hours during at least the ﬁrst 24 hours. In
view of the frequent presence of renal insufﬁciency in these
patients, however, myocardial necrosis was assessed by
levels of CK-MB. Initial treatment included oxygen by mask,
intravenous morphine sulphate, intravenous infusion of nitro-
glycerin, and intravenous furosemide. Sodium nitroprusside
was added whenever needed, whereas hypotension was
initially treated with dobutamine and/or noradrenaline.
Patients with persistent respiratory insufﬁciency underwent
noninvasive ventilatory support, whereas oral intubation and
mechanical ventilation were instituted in cases of refractory
hypoventilation. Angiotensin-converting enzyme (ACE) inhibi-
tors or angiotensin receptors antagonists and beta-blockers
were added in the subacute phase of the disease. These drugs
along with diuretics were the main line of therapy for heart
failure at hospital discharge. In recent years, aldosterone
antagonists were also recommended. Additional medications
were added according to the underlying heart disease. Also,
coronary revascularization procedures, surgical treatment of
valvular heart disease, and follow-up management were
dictated by the attending physicians that were largely within
the recommendations of appropriate international guidelines.
Echocardiographic Study and Coronary
Angiography
A two-dimensional echocardiogram Doppler (Vivid 3 or Vivid i
with harmonic imaging; General Electric, Fairﬁeld, CT) was
performed within 6 hours from admission. Left ventricular
end-diastolic and end-systolic diameters were measured, and
ejection fraction was calculated by the Simpson method;
thickness of septal and posterior walls was measured in the
long parasternal views. The presence of valvular disease was
also investigated and the existence of mitral regurgitation was
assessed by a semiquantitative approach by Doppler ﬂow
mapping (color). It was judged to be mild, moderate, or severe
when the regurgitant jet occupied 5% to 19%, 20% to 39%, or
≥40% of the left atrial area, respectively. To assess diastolic
function, diastolic transmitral ﬂow velocities were recorded in
the standard apical 4-chamber view with the sample volume
positioned at the mitral leaﬂet tips. The ratio between peak
velocities of the E and A waves and the deceleration time
were evaluated. The ﬂow at the pulmonary veins was also
analyzed, and diastolic inﬂow was categorized as normal,
impaired relaxation, pseudonormalization, or restrictive
patterns.
Coronary angiography was intended to be performed in
most patients and was interpreted by 2 observers who visually
evaluated by consensus the number of main coronary vessels
with ≥70% stenosis. The protocol complied with the Decla-
ration of Helsinki and was approved by the hospital ethics
committee, and informed consent was obtained from patients
before entering the study.
Underlying heart disease
Two cardiac conditions were recognized: CAD and non-CAD.
Diagnosis of CAD was based on ≥1 of the following criteria:
(1) previous myocardial infarction (pathological Q waves in ≥2
contiguous leads, enzyme rise, or a ﬁxed perfusion defect in
myocardial scintigraphic studies); (2) acute coronary syn-
dromes: acute myocardial infarction with increased levels of
CK-MB mass >10 lg/L (upper normal limit: 6 lg/L) with or
without chest pain or ECG changes, or unstable angina, also
with or without chest pain but with transient ECG changes and
CKMB mass ≤10 lg/L; or (3) coronary stenosis ≥70% in ≥1
major epicardial vessel. The non-CAD group included patients
with a primary moderate-severe valvular heart disease, those
with dilated (left ventricular end-diastolic diameter ≥65 mm)
or hypertrophic (wall thickness ≥15 mm) cardiomyopathy and
those with no apparent heart disease. Patients with myocar-
dial infarction and valvular heart disease, however, were
categorized as CAD, whereas those with severe valvular heart
disease (severe aortic stenosis, mitral stenosis, or aortic
regurgitation) and small myocardial infarction (CK-MB
<20 lg/L) were classiﬁed as non-CAD.
Statistical Analysis
We compared clinical, electrocardiographic, and echocardio-
graphic and clinical outcome between CAD and non-CAD
patients. We also compared the proﬁle of hospital survivors
and nonsurvivors and that of long-term follow-up survivors
and nonsurvivors. We used the Student t test for comparison
of 2 continuous variables with normal distribution, the Mann–
Whitney U test for variables with abnormal distribution, and
the chi-square or the Fisher exact test to compare categorical
variables. A multivariable logistic regression analysis exam-
ined the predictive value of variables associated with in-
hospital mortality in a univariate analysis, whereas a Cox
regression analysis was used for predictors of overall
mortality. Long-term survival was estimated by the Kaplan-
Meier method. The analysis was performed with SPSS
software (version 15.0; SPSS, Inc., Chicago, IL), data
expressed as meanSD, and differences considered signiﬁ-
cant at P<0.05.
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Results
There were 638 patients with CAD and 168 without, of whom
111 had valvular heart disease, 18 a cardiomyopathy, and 39
no apparent heart disease. Moderate-to-severe mitral insuf-
ﬁciency, aortic stenosis, and mitral stenosis were judged to be
the main valvular disorders in 68, 26, and 17 non-CAD
patients, respectively.
Demographic, Echocardiographic, and
Angiographic Data
In most patients, APE was a de novo presentation since 85%
of CAD and 84% of non-CAD cases had no previous episodes.
CAD patients were older (7310 vs 6713 years; P<0.001)
and had a higher rate of diabetes (50% vs 35%; P=0.001) and
peripheral vascular disease (30% vs 14%; P<0.001) than non-
CAD patients, but showed a lower incidence of chronic atrial
ﬁbrillation (15% vs 30%; P<0.001). They also presented a
lower ejection fraction (40.712.4% vs 50.217.0%;
P<0.001). Coronary angiography was performed in 506
patients (63%), 69% from the CAD group, and 43% from the
non-CAD group. Signiﬁcant coronary disease was present in
94% and 32%, respectively, with a predominance of multives-
sel disease in the former (80%).
In-Hospital Outcome
In-hospital mortality occurred in 222 patients (27.5%) and
tended to be lower in the CAD (169, 26.5%) than in the non-
CAD group (53; 31.5%; P=0.169; Figure 1). The cause of
death was identiﬁed in 221 patients and was strictly cardiac
in 110 cases (50%), mostly cardiogenic shock or recurrence of
APE, whereas in 95 (42.8%) it was associated with compli-
cations of the pulmonary edema or a transiently impaired
hemodynamic condition. The proportion of cardiac deaths in
CAD and non-CAD patients was similar (49.4% vs 38.5%;
P=0.200). Nonsurvivors were older than survivors in the 2
groups and had a lower admission blood pressure and lower
heart rate. They also had greater impairment of left ventricular
diastolic function. Ejection fraction was also lower in nonsur-
vivors than in survivors in the CAD group, but not in the non-
CAD group where it was higher in nonsurvivors (Table 1). In
both groups, nonsurvivors were less frequently treated with
ACE inhibitors, mostly because they had continued with
nitroglycerin infusion, and were more frequently intubated or
treated with dobutamine. Recurrence of APE was more often
observed in nonsurvivors of the CAD group and in 46 patients
(41.1%) it was associated with in-hospital angina or myocar-
dial infarction. Moreover, the incidence of in-hospital myocar-
dial infarction or reinfarction was also higher in nonsurvivors
than in survivors (Table 2). Of the 113 CAD patients with
either in-hospital angina, myocardial infarction, or recurrent
APE, nonrevascularized patients showed a strong trend
toward a higher mortality than the revascularized ones (31
of 52 [59.6%] vs 25 of 61 [41%]; P=0.060).
A multivariable analysis revealed that advanced age,
admission systolic blood pressure, recurrence of APE, and
need for inotropics or endotracheal intubation were the most
signiﬁcant independent markers of hospital mortality
(Table 3).
Follow-up Events
Of the 584 hospital survivors, there were 10 with a missing
follow-up (1.2%), all from the CAD group, and median follow-
up for the 258 total survivors was 45 months (range, 10–40).
There were 316 deaths that resulted in a follow-up mortality
of 55.1% (316 of 574) that was higher in CAD than in non-CAD
patients (273 of 459 [59.5%] vs 43 of 115 [37.4%]; P<0.001;
Table 2; Figure 1). In the 2 groups, nonsurvivors were older
than survivors and showed a higher rate of peripheral vascular
disease, a higher creatinine, and lower hemoglobin levels.
Nonsurvivors underwent less frequently coronary revascular-
ization procedures or valve replacement than survivors,
although this was often attributable to notable comorbidities
(Table 2). Among survivors, hospital readmissions for nonfatal
heart failure were higher in CAD than in non-CAD patients
(17.3% vs 7.6%; P=0.009). Cause of death in the follow-up
could be determined in 226 of 316 patients (72%), 192 of 273
with CAD (70%), and 34 of 43 with non-CAD (79%). Death was
of cardiac origin in 85 of 226 patients (38%), 76 of 192 of
those with CAD (40%), and 9 of 34 of those with non-CAD
(27%; P=0.180).
Figure 1. Among patients with APE, those with CAD presented a
higher follow-up and total mortality than those with non-CAD,
whereas in-hospital mortality was similar. APE indicates acute
pulmonary edema; CAD, coronary artery disease.
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Table 2. Hospital and Follow-up Management and Events in Patients With APE
In-Hospital Course (n=806) Follow-Up (n=574)
Non-CAD (n=169)
Survivors
P Value
CAD (n=638)
Survivors
P Value
Non-CAD (n=115)
Survivors
P Value
CAD (n=479)
Survivors
P ValueYes (116) No (53) Yes (469) No (169) Yes (72) No (43) Yes (186) No (273)
Hospital treatment
Beta-blockers 46% 52% 0.205 65% 48% 0.001 39% 58% 0.045 67% 64% 0.487
Nitrates 96% 94% 0.710 96% 89% <0.001 94% 98% 0.411 95% 96% 0.615
ACE inhibitors 71% 45% 0.001 95% 62% <0.001 75% 65% 0.257 93% 97% 0.092
Diuretics 100% 100% 1.0 99% 100% 0.297 100% 100% 1.0 99% 100% 0.381
Aspirin 11% 13% 0.723 99% 99% 0.367 8% 16% 0.193 97% 99% 0.109
Dihydroperidines 7% 2% 0.175 38% 31% 0.078 8% 5% 0.453 49% 31% <0.001
Dobutamine 24% 49% 0.001 18% 59% <0.001 24% 26% 0.812 22% 15% 0.054
Noradrenaline 17% 46% <0.001 17% 53% <0.001 14% 24% 0.233 18% 17% 0.794
Endotracheal intubation 20% 47% <0.001 16% 54% <0.001 18% 23% 0.500 17% 15% 0.695
CPAP 29% 39% 0.201 24% 37% 0.002 33% 21% 0.177 31% 19% 0.004
Thrombolytics 0% 0% 6% 9% 0.222 0% 0% 5% 8% 0.268
Primary PCI 0% 0% 7% 13% 0.075 0% 0% 11% 6% 0.053
Interventions 0.296 0.091 0.008 <0.001
Late PCI 4% 0% 24% 18% 0% 0% 27% 22%
CABG 0% 0% 7% 4% 6% 0% 14% 4%
Valvular surgery 23% 23% 3% 7% 33% 11% 20% 2%
Hospital events
Angina 2% 9% 0.074 10% 18% 0.020 0% 0% 6% 14% 0.009
Myocardial infarction 0% 0% 1.5% 13% <0.001 0% 0% 1% 2% 0.593
Recurrent APE 6% 16% 0.086 10% 32% <0.001 5% 10% 0.304 6% 14% 0.024
Follow-up treatment
Beta-blockers 50% 59% 0.384 70% 74% 0.329
Nitrates 3% 10% 0.121 30% 18% 0.003
ACE inhibitors 66% 71% 0.586 73% 78% 0.168
Diuretics 61% 8% 0.467 61% 57% 0.359
Aldosterone antagonists 20% 2% 0.307 19% 9% 0.002
Aspirin 24% 0% 0.561 71% 86% <0.001
Dihydroperidines 3% 2% 0.896 16% 7% 0.001
Calcium antagonists 14% 27% 0.103 23% 14% 0.016
Statins 49% 27% 0.024 73% 68% 0.232
Oral anticoagulants 66% 41% 0.013 29% 23% 0.126
Interventions 0.090 0.024
PCI 2.8% 7% 5.4% 1.5%
CABG 0% 1% 5.4% 2.2%
Valvular surgery 8.3% 0% 3.2% 0%
Comparison between survivors and nonsurvivors in the CAD and non-CAD groups during the in-hospital course and the follow-up (%, meanSD). ACE indicates angiotensin-converting
enzyme; APE, acute pulmonary edema; CABG, coronary artery bypass surgery; CPAP, continuous positive airway pressure, noninvasive ventilation; CVA cerebrovascular accident; PCI,
percutaneous coronary intervention.
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Overall Mortality
Total mortality was high (538 of 796; 67.6%) and was higher in
CAD (442 of 628; 70.4%) than in non-CAD patients (96 of 168
[57.1%]; P<0.002; Figures 1 through 3), and this difference
remained apparent in subsets with different age (Figure 2).
Cardiac mortality among patients with known cause of death
tended to be higher in CAD (158 of 361 [43.8%] vs 29 of 87
[33.3%]; P=0.090). A Cox regression analysis disclosed that
advanced age, peripheral vascular disease, and peak CK-MB
during hospitalization index were the main independent
predictors of mortality, whereas coronary revascularization
or valvular surgery were signiﬁcantly protective (Table 3).
Most of these interventions were performed during hospital-
ization index (294 of 307; 96%), and patients who did not
undergo these procedures were older (7310 vs
7010 years; P<0.001) and more often female (42% vs
29%; P<0.001), and had a higher rate of peripheral vascular
disease (32% vs 22%; P=0.004) and previous renal insufﬁ-
ciency (25% vs 19%; P=0.057) than those not intervened.
Ejection fraction, however, was similar in survivors and
nonsurvivors in the 2 groups.
Discussion
The principal ﬁndings of our study were: (1) a high hospital
mortality that was similar in CAD and non-CAD patients and
that was mostly secondary to a cardiac cause or to
complications derived from APE; (2) a higher 4-year mortality
and hospital readmission rate for nonfatal heart failure in CAD
than in non-CAD patients; and (3) the existence of different
predictors of hospital and overall mortality.
In-Hospital Outcome
Several investigators have reported on the in-hospital mor-
tality in patients with acute heart failure, which is an ample
concept that includes acute decompensation of chronic heart
failure, cardiogenic shock with or without pulmonary edema,
right ventricular failure, and APE.3,6,14,19–21 In these studies,
mortality has varied from 6.4% to 17.2% and they have shown
advanced age,6,14,19,21 severe left ventricular dysfunction,14
acute coronary syndromes,14 admission blood pressure,6,19,21
renal failure,6,19,21 need for inotropics,19 and anemia19 as
principal predictors.
In patients with APE, in-hospital mortality seems compa-
rable to patients with acute heart failure ranging also from
7.4% to 17%,7,10,18,22,23 although in small and earlier
reports,7,18 mortality was higher (12% and 17%) than in
larger, more recent studies (7.4%–9.6%).10,22,23 Nevertheless,
in patients admitted to critical care areas—such as in our
study—hospital mortality is higher (32%), at least in the only
reported series that involved 199 patients.24 In our work,
hospital mortality was somewhat lower (25%), but it was
higher than in patients not admitted to critical care
areas,7,10,18,22,23 likely because of the more severe respira-
tory and/or hemodynamic condition, as indicated by the high
need for endotracheal intubation or inotropic agents (26% and
29%), respectively. Another possible explanation was the high
proportion of de novo cases of APE (>80%), a fact that has
also been associated with higher hospital mortality.20 In
Figure 2. Total mortality in patients with APE and CAD was
higher than in those with non-CAD across the groups of different
age (P=0.018) (numbers within brackets indicate CAD and non-CAD
cases). APE indicates acute pulmonary edema; CAD, coronary
artery disease.
Figure 3. Kaplan–Meier survival curve showing a strong trend
toward higher mortality in patients with APE and CAD that was
mainly apparent during the follow-up. APE indicates acute
pulmonary edema; CAD, coronary artery disease.
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comparison with existing series,7,10,18,22,23 we found similar
major in-hospital mortality markers, such as age, admission
blood pressure, and the need for endotracheal intubation or
inotropic agents. Nevertheless, we observed additional strong
predictors not previously reported, such as moderate-to-
severe mitral regurgitation and hospital recurrence of APE.
The former was present in more than one third of patients and
in a similar proportion of those with or without CAD, whereas
the latter occurred more frequently in CAD patients and could
be partly attributed to myocardial ischemia because in 46% it
was associated with recurrence of angina or myocardial
infarction.
Total Mortality
Most series that have analyzed total mortality in patients with
acute heart failure have reported only a 1-year follow-up with
mortality rates ranging from 17.4% to 34%5,11–14 and higher in
patients admitted to a critical care area (46.5%).4 Predictors
of 1-year mortality appeared also to be age,12–15 admission
blood pressure,13,15 anemia,13 renal failure,12,13,15 left ven-
tricular dysfunction, and acute coronary syndromes.14 There
are few studies (3), however, that have analyzed a longer
follow-up in patients with acutely decompensated heart
failure,15–17 with mortality rates of 60.3%15 and 71%,16 with
similar main predictors than in the 1-year follow-up series.15
In contrast to acute heart failure, only 2 studies have
investigated the 1-year mortality in patients with APE7,18 and
none has analyzed a longer follow-up. The 2 studies were
carried out nearly 2 decades ago and included 8618 and 150
patients7 with amortality of 51.2% and 40%, respectively. In the
present work, which ismostly an investigation of a de novo APE,
the 4-year mortality was 62%, and was higher in CAD than in
non-CAD patients. Moreover, death was more frequently of
noncardiac origin, particularly in non-CAD patients. Most
signiﬁcant independent markers were age, peripheral vascular
disease, and peak CK-MB during hospitalization index.
Hospital readmission rate for APE or acute decompensated
heart failure was also higher in CAD than in non-CAD patients.
As expected, revascularized CAD patients and those with non-
CADwho had valvular replacement showed a lower hospital and
long-term mortality or recurrence of heart failure than those
without these procedures. Indeed, the Cox regression analysis
showed that practice of coronary revascularization or valvular
surgery was signiﬁcantly protective. Revascularization or valve
replacement procedures, however, were less frequently per-
formed in elderly patients mainly because of relevant comor-
bidities. Noteworthy, the more severe prognosis of CAD
patients is likely multifactorial because they were older and
had a higher rate of peripheral vascular disease, diabetes, and
multivessel coronary disease conditions that portends a more
severe arteriosclerotic proﬁle. It is unclear why ejection fraction
was not a marker of mortality, but, in part, this may relate to the
rather high incidence of noncardiac deaths.
Strengths and Limitations
Relevant ﬁndings of our study and not previously reported are
the 4-year prognosis of patients with APE and the comparison
of outcomes between patients with and without CAD. Also of
importance is the fact that identiﬁcation of CAD patients was
based not only on clinical grounds, but also on coronary
angiography data available in 69% of them, but also in 43% of
those with non-CAD. This is in contrast to most existing series
of APE7,10,23 or acute heart failure,1–5,13 where angiographic
data are not provided. Of interest is the documentation of
signiﬁcant coronary artery stenosis in 32% of non-CAD
patients who underwent cardiac catheterization, pointing to
the concomitant presence of CAD in patients with the primary
diagnosis of valvular heart disease. In addition, all our patients
had an echocardiogram during the ﬁrst few hours from
Table 3. Multivariable Predictors of In-Hospital and Overall
Mortality in Patients With APE
OR 95% CI P Value
In-hospital mortality
Age (per year) 1.062 1.031 to 1.092 <0.001
Endotracheal intubation 2.733 1.573 to 4.772 <0.001
Dobutamine 2.910 1.642 to 5.711 <0.001
Recurrent APE 2.414 1.362 to 4.273 0.003
Admission systolic blood
pressure (per mm Hg)
0.993 0.984 to 0.988 0.008
CAD 1.842 1.102 to 3.081 0.020
Overall mortality
Age (per year) 1.028 1.021 to 1.073 <0.001
Peripheral vascular disease 1.672 1.683 to 4.532 <0.001
Peak CKMB, per lg/L 1.001 1.000 to 1.002 0.001
Coronary revascularization—
valvular surgery
0.883 0.785 to 0.988 0.001
Diabetes 1.353 1.059 to 1.719 0.015
Mitral insufficiency 1.164 1.034 to 1.303 0.015
Chronic obstructive
pulmonary disease
1.392 1.066 to 1.807 0.015
Creatinine, per mg/dL 1.113 1.020 to 1.217 0.016
Aortic stenosis 1.201 1.026 to 1.391 0.022
Dobutamine 1.741 1.269 to 2.389 0.031
Female sex 1.323 1.008 to 1.737 0.043
Main hospital and overall mortality predictors using a single model with multiple
predictors are listed with the corresponding units in continuous variables or as the
presence of categorical variables. CAD indicates coronary artery disease; CK-MB,
creatine kinase MB; OR, odds ratio.
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hospital admission to evaluate the underlying heart disease.
Follow-up was long and thorough given that only 1.7% of
patients were lost, and in 73% the cause of death could be
identiﬁed. As limitations, we recognized that our results may
not be applicable to patients with previous admission with
APE because in 85% it was a ﬁrst event, or to those admitted
to a regular ward rather than to a critical care area. Another
drawback is the fact that only a minority of patients were
treated with aldosterone antagonists. This, in part, may be
explained by the years in which the study was carried out and
also by the not infrequent presence of moderate renal failure.
Implications
Our results indicate that APE—at least in patients with a ﬁrst
episode admitted to an acute cardiac care unit—is associated
with a high hospital and 4-year mortality, particularly in those
with CAD. In the latter subset, the role of advanced
arteriosclerosis in their poor prognosis is underscored. On
the other hand, coronary revascularization and valvular
surgery signiﬁcantly reduced overall mortality. Thus, identify-
ing high-risk patients for in-hospital and long-term mortality,
in part, through the predictors herein described—which do
not necessarily implicate the systolic function—we may
speculate that a more aggressive interventional program
might improve survival in high-risk patients despite the
frequent comorbidities. In keeping with this and in view of
the fact that recurrence of in-hospital APE—one of the
markers of in-hospital mortality—was often caused by
recurrent symptomatic or silent myocardial ischemia, an
increase in the frequency of coronary angiography and early
revascularization might have improved their outcome.
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